Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1020034 | 0.88 | ACKR3 (0.50) | ACKR3 | |
| SCHEMBL1019694 | 0.88 | HTT (0.44) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3688230 | 0.86 | ACKR3 (0.51) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1020415 | 0.86 | HTT (0.46) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1018507 | 0.86 | ACKR3 (0.46) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1019141 | 0.85 | ACKR3 (0.43) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1019490 | 0.84 | ALDH1A1 (0.50) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL1020248 | 0.83 | PRKAB2 (0.48) | ACKR3MEN1KMT2A | |
| SCHEMBL1072854 | 0.83 | ACKR3 (0.42) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1019162 | 0.83 | MEN1 (0.44) | ACKR3ALDH1A1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314091-B2 | N-benzyl,N'-arylcarbonylpiperazine derivatives | MSD OSS B.V. (NL) | 2012-11-20 | — | — | US | disclosed |
| EP-2190827-B1 | N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS | ORGANON NV (NL) | 2011-01-12 | — | — | EP | disclosed |
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | N.V. ORGANON AND PHARMACOPEIA, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264416-A1 | N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES | NPC1L1, NPC1, ABCB11 | ACKR3 1939/4885ALDH1A1 1749/4885TACR2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.